How Investors Are Reacting To Ardelyx (ARDX) Hedge Fund Buying Despite Medicare Setback

Simply Wall St.07-23

In recent months, Ardelyx has drawn attention as Wall Street forecasts a shift from losses to profits, supported by strong Ibsrela prescription growth and long-dated patents, even as the company lost ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2653279539?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-07-23 03:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2653279539","market":"sg","top_or_hot":-1,"title":"How Investors Are Reacting To Ardelyx (ARDX) Hedge Fund Buying Despite Medicare Setback","media":"Simply Wall St.","content":"<div>\n<p>In recent months, Ardelyx has drawn attention as Wall Street forecasts a shift from losses to profits, supported by strong Ibsrela prescription growth and long-dated patents, even as the company lost ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ardx/ardelyx/news/how-investors-are-reacting-to-ardelyx-ardx-hedge-fund-buying\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Investors Are Reacting To Ardelyx (ARDX) Hedge Fund Buying Despite Medicare Setback</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Investors Are Reacting To Ardelyx (ARDX) Hedge Fund Buying Despite Medicare Setback\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-23 03:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ardx/ardelyx/news/how-investors-are-reacting-to-ardelyx-ardx-hedge-fund-buying><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In recent months, Ardelyx has drawn attention as Wall Street forecasts a shift from losses to profits, supported by strong Ibsrela prescription growth and long-dated patents, even as the company lost ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ardx/ardelyx/news/how-investors-are-reacting-to-ardelyx-ardx-hedge-fund-buying\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PMDE","symbol_name":"PGIM S&P 500 Max Buffer ETF - December","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ardx/ardelyx/news/how-investors-are-reacting-to-ardelyx-ardx-hedge-fund-buying","article_id":"2653279539","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ardx/ardelyx/news/how-investors-are-reacting-to-ardelyx-ardx-hedge-fund-buying","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2653279539","pubTimestamp":1784748314,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In recent months, Ardelyx has drawn attention as Wall Street forecasts a shift from losses to profits, supported by strong Ibsrela prescription growth and long-dated patents, even as the company lost its appeal for separate Medicare payments on dialysis drug Xphozah.\nAn interesting angle is that hedge funds have been increasing their positions in Ardelyx despite the Medicare setback, suggesting institutional investors remain focused on the company’s earnings turnaround potential and...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"PMDE":"PGIM S&P 500 Max Buffer ETF - December","RGLO":"Global Equity Active ETF","VOTE":"TCW Transform 500 ETF","DECU":"AllianzIM U.S. Equity Buffer15 Uncapped Dec ETF","FEBU":"AllianzIM U.S. Equity Buffer15 Uncapped Feb ETF","LNGR":"Global X Longevity Thematic ETF","ARDX":"Ardelyx","BK4139":"生物科技","GXDW":"Global X Dorsey Wright Thematic ETF","BK4211":"区域性银行","JOYT":"JPMorgan Equity and Options Total Return ETF","ISBC":"投资者银行","VGFPF":"Vanguard Funds PLC"},"translate_title":"尽管医疗保险受挫，投资者对 Ardelyx (ARDX) 对冲基金购买有何反应","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VOTE":0.72,"DECU":0.72,"ARDX":1.5,"JOYT":0.72,"VGFPF":0.72,"FEBU":0.72,"ISBC":1.5,"LNGR":1.5,"RGLO":0.72,"GXDW":0.72,"PMDE":0.72},"content_text":"In recent months, Ardelyx has drawn attention as Wall Street forecasts a shift from losses to profits, supported by strong Ibsrela prescription growth and long-dated patents, even as the company lost its appeal for separate Medicare payments on dialysis drug Xphozah. An interesting angle is that hedge funds have been increasing their positions in Ardelyx despite the Medicare setback, suggesting institutional investors remain focused on the company’s earnings turnaround potential and management’s long-term sales ambitions for Ibsrela. We’ll now explore how this improving earnings outlook, underpinned by Ibsrela’s momentum, may affect Ardelyx’s existing investment narrative. Outshine the giants: these 16 early-stage AI stocks could fund your retirement.AdvertisementArdelyx Investment Narrative RecapTo own Ardelyx, you need to believe Ibsrela can carry the business from consistent losses toward sustained profitability, while Xphozah contributes despite its Medicare setback. The recent loss of the Xphozah payment appeal keeps reimbursement risk front and center, but the immediate earnings catalyst still hinges on upcoming results that confirm Ibsrela’s prescription strength and validate Wall Street’s profit swing expectations. One of the most relevant recent developments here is Ardelyx reaffirming its 2026 revenue guidance, including US$410–US$430 million for Ibsrela and US$110–US$120 million for Xphozah. Against the backdrop of rising hedge fund ownership, this guidance anchors the near term earnings turnaround story and frames how much room there is for upside or disappointment around the next earnings report. But while Ibsrela’s rise is encouraging, investors should also be aware that Ardelyx’s dependence on just two tenapanor based products means... Read the full narrative on Ardelyx (it's free!)Ardelyx's narrative projects $1.0 billion revenue and $317.0 million earnings by 2029.Uncover how Ardelyx's forecasts yield a $16.33 fair value, a 221% upside to its current price.Exploring Other PerspectivesARDX 1-Year Stock Price Chart Some of the most optimistic analysts were previously modeling about US$1.1 billion in 2029 revenue and roughly US$425.8 million in earnings, which is far more upbeat than consensus. In light of the recent Medicare setback and shifting expectations around Xphozah, you should recognize that these bullish views might need revisiting and that reasonable people can reach very different conclusions about Ardelyx’s future.Explore 6 other fair value estimates on Ardelyx - why the stock might be worth just $13.00!Form Your Own VerdictDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your Ardelyx research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.Our free Ardelyx research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ardelyx's overall financial health at a glance.Ready For A Different Approach?The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2653279539","isCrawlerRequest":true}